Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 10,795 shares at $8.91 ($84K) on 2019-05-30, disclosed to the SEC on 2019-06-03.
Scheduled purchase ($84k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.91 | 300 | $3K | 3.2% |
| 2 | $7.70 | 5,071 | $39K | 46.7% |
| 3 | $7.71 | 5,424 | $42K | 50.1% |
| Total | $7.74 avg | 10,795 | $84K | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $262K | — | Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| UROV | BUY | 2019-06-11 | $292K | — | Filing → |